USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: HAEMATOLOGIC TECHNOLOGIES, INC.
City: ESSEX JUNCTION
State: VT
Zip+4: 05452
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $377,817.00 6
SBIR Phase II $1,510,119.00 3
STTR Phase I $99,039.00 1
STTR Phase II $702,513.00 1

Award List:

IMMUNOASSAY FOR OSTEOCALCIN FRAGMENTS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $46,139.00
Abstract:
Currently, an assay to measure the rate of bone resorption in an easy and reproducible manner does not exist. osteocalcin, a bone-specific protein, is assayed as a marker of bone formation. since there is reasonable evidence that fragments of bone proteins are liberated by the resorptive process, an… More

SELECTIVE CAPTURE AND QUANTITATION OF SERINE PROTEASES

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

SELECTIVE CAPTURE AND QUANTITATION OF SERINE PROTEASES

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $500,000.00
Abstract:
Thrombosis and thrombolysis are maintained in a delicate balance by a series of enzymatic reactions. the component enzymes are produced as needed from zymogens, inactive forms that circulate in the blood at relatively high concentrations. identifying and evaluating patients at riskfor clinical… More

Assay for In Vivo Activated Protein C (APC) Activity

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard Jenny
Award Amount: $58,396.00
Abstract:
In the area of clinical coagulation research, much attention is focused on the molecular eventswhich occur before, during, and after anticoagulant and antithrombotic therapies. For purposes ofmonitoring the safety, efficacy and long-term effects of such therapies, there exist a number ofcommercially… More

Specific Inhibitors of Activated Protein C

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard Jenny
Award Amount: $74,065.00
Abstract:
Factors V and VIII are procofactors which are essential components of the blood coagulationprocess. Deficiency in either of these proteins is associated with severe bleeding disorders, hemophiliaand para-hemophilia. Deficiency states of these proteins can be caused by their proteolytic… More

Murine Reagents and Analytical Tools

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ryan H. Dorfman
Award Amount: $75,000.00
Abstract:
DESCRIPTION (provided by applicant): The mechanisms that govern blood coagulation and fibrinolysis have been studied extensively by employing a variety of experimental techniques and in-vivo model systems. Recently gene targeting (knockout mice) and transgenic techniques have been employed to create… More

Fluorogenic Assays for Factor Vlla and Tissue Factor

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard J. Jenny
Award Amount: $74,217.00
Abstract:
DESCRIPTION (provided by applicant): Factor Vlla and Tissue Factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor Vlla. The factor Vlla/TF… More

A Global Test of Hemostatic Risk

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
Principal Investigator: Richard J. Jenny
Award Amount: $99,039.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Although the vast majority of patients who suffer from venous or arterial thrombosis have haemostatic systems that fall within the "normal" range of routine screening tools such as PT, aPTT, and factor assays, thrombosis is the major cause of death in Western… More

Murine Reagents and Analytical Tools

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ryan H. Dorfman
Award Amount: $681,228.00
Abstract:
DESCRIPTION (provided by applicant): The mechanisms that govern blood coagulation and fibrinolysis have been studied extensively by employing a variety of experimental techniques and in-vivo model systems. Recently gene targeting (knockout mice) and transgenic techniques have been employed to create… More

Fluorogenic Assays for Factor Vlla and Tissue Factor

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard Jenny
Award Amount: $328,891.00
Abstract:
DESCRIPTION (provided by applicant): Factor VIIa and tissue factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor VIla. The factor Vlla/TF… More